{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T09:09:18Z","timestamp":1779527358345,"version":"3.53.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40744-026-00834-5","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T10:33:27Z","timestamp":1773398007000},"page":"611-628","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Upadacitinib on Reducing Pain in Patients Across the Axial Spondyloarthritis Spectrum: A Post Hoc Analysis of the Phase 2\/3 SELECT-AXIS Studies"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9475-9362","authenticated-orcid":false,"given":"Xenofon","family":"Baraliakos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Bessette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"de Vlam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Biljan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Urbanik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianming","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria S.","family":"Jasion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Lippe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Magrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"834_CR1","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1136\/annrheumdis-2023-eular.3918","volume":"82","author":"X Baraliakos","year":"2023","unstructured":"Baraliakos X, Magrey M, Bessette L, de Vlam K, Gao T, Shmagel A, et al. Effect of upadacitinib on reducing pain in patients with active ankylosing spondylitis and inadequate response to biologic therapy. Ann Rheum Dis. 2023;82:1691\u20132.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"834_CR2","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1136\/ard-2023-225185","volume":"83","author":"D van der Heijde","year":"2023","unstructured":"van der Heijde D, Molto A, Ramiro S, Braun J, Dougados M, van Gaalen FA, et al. Goodbye to the term \u2018ankylosing spondylitis\u2019, hello \u2018axial spondyloarthritis\u2019: time to embrace the ASAS-defined nomenclature. Ann Rheum Dis. 2023;83(5):547\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"10089","key":"834_CR3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","volume":"390","author":"J Sieper","year":"2017","unstructured":"Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet. 2017;390(10089):73\u201384.","journal-title":"Lancet"},{"issue":"4","key":"834_CR4","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1177\/0300060513488501","volume":"41","author":"M Hammoudeh","year":"2013","unstructured":"Hammoudeh M, Zack DJ, Li W, Stewart VM, Koenig AS. Associations between inflammation, nocturnal back pain and fatigue in ankylosing spondylitis and improvements with etanercept therapy. J Int Med Res. 2013;41(4):1150\u20139.","journal-title":"J Int Med Res"},{"issue":"1","key":"834_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-017-1333-x","volume":"19","author":"L van Hoeven","year":"2017","unstructured":"van Hoeven L, Boonen AERCH, Hazes JMW, Weel AEAM. Work outcome in yet undiagnosed patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis; results of a cross-sectional study among patients with chronic low back pain. Arthritis Res Ther. 2017;19(1):143.","journal-title":"Arthritis Res Ther"},{"key":"834_CR6","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X20966123","volume":"12","author":"C L\u00f3pez-Medina","year":"2020","unstructured":"L\u00f3pez-Medina C, Molt\u00f3 A. Comorbid pain in axial spondyloarthritis, including fibromyalgia. Ther Adv Musculoskelet Dis. 2020;12:1759720X20966123.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"6","key":"834_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-016-0581-0","volume":"18","author":"SD Boyden","year":"2016","unstructured":"Boyden SD, Hossain IN, Wohlfahrt A, Lee YC. Non-inflammatory causes of pain in patients with rheumatoid arthritis. Curr Rheumatol Rep. 2016;18(6):30.","journal-title":"Curr Rheumatol Rep"},{"issue":"Suppl 1","key":"834_CR8","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1186\/1478-6354-13-S1-S4","volume":"13","author":"G Schett","year":"2011","unstructured":"Schett G, Coates LC, Ash ZR, Finzel S, Conaghan PG. Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future. Arthritis Res Ther. 2011;13(Suppl 1):S4.","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"834_CR9","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1093\/rheumatology\/keac671","volume":"62","author":"D Das","year":"2022","unstructured":"Das D, Choy E. Non-inflammatory pain in inflammatory arthritis. Rheumatology. 2022;62(7):2360\u20135.","journal-title":"Rheumatology"},{"issue":"1","key":"834_CR10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2022-223296","volume":"82","author":"S Ramiro","year":"2023","unstructured":"Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82(1):19\u201334.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"834_CR11","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/art.41042","volume":"71","author":"MM Ward","year":"2019","unstructured":"Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, et al. 2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2019;71(10):1599\u2013613.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"834_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1565-4","volume":"20","author":"M Haroon","year":"2018","unstructured":"Haroon M, Ahmad M, Baig MN, Mason O, Rice J, FitzGerald O. Inflammatory back pain in psoriatic arthritis is significantly more responsive to corticosteroids compared to back pain in ankylosing spondylitis: a prospective, open-labelled, controlled pilot study. Arthritis Res Ther. 2018;20(1):73.","journal-title":"Arthritis Res Ther"},{"key":"834_CR13","volume":"10","author":"S Ramiro","year":"2011","unstructured":"Ramiro S, Radner H, van der Heijde D, van Tubergen A, Buchbinder R, Aletaha D, et al. Combination therapy for pain management in inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis). Cochrane Database Syst Rev. 2011;10:CD008886.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"834_CR14","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1136\/annrheumdis-2017-212662","volume":"77","author":"R Geenen","year":"2018","unstructured":"Geenen R, Overman CL, Christensen R, \u00c5senl\u00f6f P, Capela S, Huisinga KL, et al. EULAR recommendations for the health professional\u2019s approach to pain management in inflammatory arthritis and osteoarthritis. Ann Rheum Dis. 2018;77(6):797\u2013807.","journal-title":"Ann Rheum Dis"},{"key":"834_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-018-0031-x","volume":"2","author":"JM Parmentier","year":"2018","unstructured":"Parmentier JM, Voss J, Graff C, Schwartz A, Argiriadi M, Friedman M, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2018;2:23.","journal-title":"BMC Rheumatol"},{"key":"834_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13688","volume":"17","author":"MF Mohamed","year":"2024","unstructured":"Mohamed MF, Bhatnagar S, Parmentier JM, Nakasato P, Wung P. Upadacitinib: mechanism of action, clinical, and translational science. Clin Transl Sci. 2024;17:e13688.","journal-title":"Clin Transl Sci"},{"key":"834_CR17","doi-asserted-by":"publisher","first-page":"1341981","DOI":"10.3389\/fimmu.2024.1341981","volume":"15","author":"C Selmi","year":"2024","unstructured":"Selmi C, Chimenti MS, Novelli L, Parikh BK, Morello F, de Vlam K, et al. Pain in axial spondyloarthritis: role of the JAK\/STAT pathway. Front Immunol. 2024;15:1341981.","journal-title":"Front Immunol"},{"issue":"11","key":"834_CR18","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1136\/ard-2022-222608","volume":"81","author":"D van der Heijde","year":"2022","unstructured":"van der Heijde D, Baraliakos X, Sieper J, Deodhar A, Inman RD, Kameda H, et al. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial. Ann Rheum Dis. 2022;81(11):1515\u201323.","journal-title":"Ann Rheum Dis"},{"issue":"10214","key":"834_CR19","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","volume":"394","author":"D van der Heijde","year":"2019","unstructured":"van der Heijde D, Song IH, Pangan AL, Deodhar A, van den Bosch F, Maksymowych WP, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial. Lancet. 2019;394(10214):2108\u201317.","journal-title":"Lancet"},{"issue":"10349","key":"834_CR20","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S0140-6736(22)01212-0","volume":"400","author":"A Deodhar","year":"2022","unstructured":"Deodhar A, van den Bosch F, Poddubnyy D, Maksymowych WP, van der Heijde D, Kim TH, et al. Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2022;400(10349):369\u201379.","journal-title":"Lancet"},{"key":"834_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-002049","volume":"8","author":"IB McInnes","year":"2022","unstructured":"McInnes IB, Ostor AJK, Mease PJ, Tillett W, Baraliakos X, de Vlam K, et al. Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials. RMD Open. 2022;8:e002049.","journal-title":"RMD Open"},{"key":"834_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002735","volume":"9","author":"GR Burmester","year":"2023","unstructured":"Burmester GR, Cohen SB, Winthrop KL, Nash P, Irvine AD, Deodhar A, et al. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open. 2023;9:e002735.","journal-title":"RMD Open"},{"key":"834_CR23","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s40744-023-00621-6","volume":"11","author":"A Rubbert-Roth","year":"2024","unstructured":"Rubbert-Roth A, Kakehasi AM, Takeuchi T, Schmalzing M, Palac H, Coombs D, et al. Malignancy in the upadacitinib clinical trials for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Rheumatol Ther. 2024;11:97\u2013112.","journal-title":"Rheumatol Ther."},{"key":"834_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003392","volume":"9","author":"C Charles-Schoeman","year":"2023","unstructured":"Charles-Schoeman C, Choy E, McInnes IB, Mysler E, Nash P, Yamaoka K, et al. MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. RMD Open. 2023;9: e003392.","journal-title":"RMD Open"},{"key":"834_CR25","doi-asserted-by":"publisher","first-page":"5215","DOI":"10.1007\/s12325-025-03328-y","volume":"42","author":"GR Burmester","year":"2025","unstructured":"Burmester GR, Deodhar A, Irvine AD, Panaccione R, Winthrop KL, Vleugels RA, et al. Safety profile of upadacitinib: descriptive analysis in over 27,000 patient-years across rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, atopic dermatitis, and inflammatory bowel disease. Adv Ther. 2025;42:5215\u201337.","journal-title":"Adv Ther."},{"key":"834_CR26","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s40744-024-00671-4","volume":"11","author":"GR Burmester","year":"2024","unstructured":"Burmester GR, Stigler J, Rubbert-Roth A, Tanaka Y, Azevedo VF, Coombs D, et al. Safety profile of Upadacitinib up to 5 years in psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis: an integrated analysis of clinical trials. Rheumatol Ther. 2024;11:737\u201353.","journal-title":"Rheumatol Ther"},{"issue":"6","key":"834_CR27","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, van der Heijde D, Landew\u00e9 R, Listing J, Akkoc N, Brandt J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777\u201383.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"834_CR28","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ejpain.2003.09.004","volume":"8","author":"F Salaffi","year":"2004","unstructured":"Salaffi F, Stancati A, Silvestri CA, Ciapetti A, Grassi W. Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale. Eur J Pain. 2004;8(4):283\u201391.","journal-title":"Eur J Pain"},{"issue":"2","key":"834_CR29","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jpain.2007.09.005","volume":"9","author":"RH Dworkin","year":"2008","unstructured":"Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9(2):105\u201321.","journal-title":"J Pain"},{"key":"834_CR30","unstructured":"Taylor P, Eder L, Klionsky Y, Proft F, Iyile T, Mancl E, et al. Early improvement of pain, long-term disease control, and quality of life outcomes in patients with psoriatic arthritis treated with upadacitinib [abstract]. Arthritis Rheumatol. 2024;76(suppl 9)."},{"key":"834_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003504","volume":"10","author":"M Garrido-Cumbrera","year":"2024","unstructured":"Garrido-Cumbrera M, Poddubnyy D, Sommerfleck F, Bundy C, Makri S, Correa-Fern\u00e1ndez J, et al. International map of axial spondyloarthritis (IMAS): results from the perspective of 5557 patients from 27 countries around the globe. RMD Open. 2024;10:e003504.","journal-title":"RMD Open"},{"issue":"1","key":"834_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1610-3","volume":"20","author":"IB McInnes","year":"2018","unstructured":"McInnes IB, Mease PJ, Schett G, Kirkham B, Strand V, Williams N, et al. Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study. Arthritis Res Ther. 2018;20(1):113.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"834_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001131","volume":"6","author":"B Fautrel","year":"2020","unstructured":"Fautrel B, Zhu B, Taylor PC, van de Laar M, Emery P, DeLeonardis F, et al. Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are na\u00efve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison. RMD Open. 2020;6(1):e001131.","journal-title":"RMD Open"},{"issue":"9","key":"834_CR34","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.3390\/jcm8091394","volume":"8","author":"B Fautrel","year":"2019","unstructured":"Fautrel B, Kirkham B, Pope JE, Takeuchi T, Gaich C, Quebe A, et al. Effect of baricitinib and adalimumab in reducing pain and improving function in patients with rheumatoid arthritis in low disease activity: exploratory analyses from RA-BEAM. J Clin Med. 2019;8(9):1394.","journal-title":"J Clin Med"},{"issue":"6","key":"834_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8060831","volume":"8","author":"PC Taylor","year":"2019","unstructured":"Taylor PC, Lee YC, Fleischmann R, Takeuchi T, Perkins EL, Fautrel B, et al. Achieving pain control in rheumatoid arthritis with baricitinib or adalimumab plus methotrexate: results from the RA-BEAM trial. J Clin Med. 2019;8(6):831.","journal-title":"J Clin Med"},{"key":"834_CR36","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/8564215","volume":"2018","author":"F Salaffi","year":"2018","unstructured":"Salaffi F, Giacobazzi G, Carlo MD. Chronic pain in inflammatory arthritis: mechanisms, metrology, and emerging targets\u2014a focus on the JAK\u2010STAT pathway. Pain Res Manag. 2018;2018:8564215.","journal-title":"Pain Res Manag"},{"key":"834_CR37","doi-asserted-by":"publisher","first-page":"668","DOI":"10.55563\/clinexprheumatol\/e7ayu8","volume":"39","author":"N Crispino","year":"2021","unstructured":"Crispino N, Ciccia F. JAK\/STAT pathway and nociceptive cytokine signalling in rheumatoid arthritis and psoriatic arthritis. Clin Exp Rheumatol. 2021;39:668\u201375.","journal-title":"Clin Exp Rheumatol"},{"issue":"suppl 1","key":"834_CR38","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.ard.2025.06.246","volume":"84","author":"D Poddubnyy","year":"2025","unstructured":"Poddubnyy D, Vassilopoulos D, Tran A, Molt\u00f3 A, Navarro-Comp\u00e1n V, Gao T, et al. Real-world effectiveness of upadacitinib on early pain control in patients with axial spondyloarthritis: interim results from the UPSTAND observational study [abstract]. Ann Rheum Dis. 2025;84(suppl 1):1023\u20135.","journal-title":"Ann Rheum Dis"},{"key":"834_CR39","unstructured":"Poddubnyy D, Navarro-Compan V, Basu N, Naffaa M, Gao T, Saffore C, et al. Impact of treatment with upadacitinib on non-nociceptive pain and its relevance for the presence of residual symptoms in axial spondyloarthritis: results from a multicountry observational study [abstract]. Arthritis Rheumatol. 2025;77(suppl 9)."}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00834-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-026-00834-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00834-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T08:46:38Z","timestamp":1779525998000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-026-00834-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["834"],"URL":"https:\/\/doi.org\/10.1007\/s40744-026-00834-5","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"7 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Financial arrangements of the authors with companies whose products may be related to the present manuscript are listed, as declared by the authors. Xenofon Baraliakos has received research grants and consultancy fees from Novartis, Pfizer, AbbVie, Eli Lilly, UCB Pharma, Galapagos, Janssen, Celgene, and Amgen. Louis Bessette has received grant\/research support from Amgen, BMS, Janssen, UCB, AbbVie, Pfizer, Merck, Celgene, Lilly, Novartis, Sanofi, and Gilead; received speaker fees from Amgen, BMS, Janssen, UCB, AbbVie, Pfizer, Merck, Celgene, Lilly, Novartis, Organon, and Sanofi; and served as an officer or board member for Amgen, BMS, Janssen, UCB, AbbVie, Pfizer, Merck, Celgene, Lilly, Novartis, Sanofi, Organon, and Gilead. Kurt de Vlam has received grant\/research support from Amgen, UCB, and MSD; consultancy fees from Amgen, AbbVie, Celgene, Eli Lilly, Galapagos, Novartis, Allegro, and UCB; and speaker fees from Amgen, Celgene, Eli Lilly, Galapagos, Novartis, and UCB. Peter C. Taylor has received grant\/research support from Alfasigma; speaker fees from AbbVie; and consulting fees from Lilly, AbbVie, Alfasigma, Gilead, Janssen, Sanofi, Nordic Pharma, UCB, Immunovant, and MoonLake. Ana Biljan, Jamie Urbanik, Tianming Gao, Victoria S. Jasion, Koji Kato, and Ralph Lippe are full-time, salaried employees of AbbVie Inc. and may\u00a0own AbbVie stock or stock options. Marina Magrey has received research grants from Amgen, AbbVie, BMS, and UCB Pharma and has received consulting fees from UCB, Novartis, Eli Lilly, Pfizer, and Janssen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Across the SELECT-AXIS 1 and SELECT-AXIS 2 trials, all patients provided written informed consent, and studies were conducted in accordance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines, applicable regulations governing clinical trial conduct, and the Declaration of Helsinki 1964 and its later amendments. As per Good Clinical Practice (GCP), the trial protocols were approved by an independent ethics committee (IEC)\/institutional review board (IRB) at each site.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}